Salt-tolerant endonucleases, the benefits for viral vector manufacturing and a comparison of two marketed enzymes

In the manufacturing of viral vectors for cell and gene therapies, as well as vaccines, the removal of residual plasmid and host cell-derived DNA and RNA is critical to meet regulatory requirements, ensure product safety, and streamline vector purification. Endonucleases enzymatically cleaving polynucleotide chains to fragments of approximately 3–5 base pairs are commonly used for this purpose. Recombinantly produced Serratia marcescens endonucleases, such as DENARASE®, are the industry standard for DNA removal in viral vector manufacturing processes. These endonucleases are typically used to reduce the plasmid and host cell DNA during viral vector harvest. It has been shown that higher salt concentrations can significantly improve viral vector solubility and reduce aggregate formation. Additionally, increased salt levels may enhance DNA accessibility for degradation, leading to higher purity and safety of the final product. However, the activity of S. marcescens endonucleases is inhibited at elevated salt concentrations. This article introduces an engineered version of the wild-type S. marcescens endonuclease, which exhibits improved tolerance to salt, thereby offering greater flexibility in bioprocessing.

Authors

Institutions

Publication Details

Journal
Cell and Gene Therapy Insights
Published
2025-03-26
DOI
https://doi.org/10.18609/cgti.2025.035
Primary Topic
Viral Infectious Diseases and Gene Expression in Insects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Salt-tolerant endonucleases, the benefits for viral vector manufacturing and a comparison of two marketed enzymes

Marc Struhalla, S M Michalek
Cell and Gene Therapy Insights
Viral Infectious Diseases and Gene Expression in Insects
article

Salt-tolerant endonucleases, the benefits for viral vector manufacturing and a comparison of two marketed enzymes

Marc Struhalla, S M Michalek
article en

Abstract

In the manufacturing of viral vectors for cell and gene therapies, as well as vaccines, the removal of residual plasmid and host cell-derived DNA and RNA is critical to meet regulatory requirements, ensure product safety, and streamline vector purification. Endonucleases enzymatically cleaving polynucleotide chains to fragments of approximately 3–5 base pairs are commonly used for this purpose. Recombinantly produced Serratia marcescens endonucleases, such as DENARASE®, are the industry standard for DNA removal in viral vector manufacturing processes. These endonucleases are typically used to reduce the plasmid and host cell DNA during viral vector harvest. It has been shown that higher salt concentrations can significantly improve viral vector solubility and reduce aggregate formation. Additionally, increased salt levels may enhance DNA accessibility for degradation, leading to higher purity and safety of the final product. However, the activity of S. marcescens endonucleases is inhibited at elevated salt concentrations. This article introduces an engineered version of the wild-type S. marcescens endonuclease, which exhibits improved tolerance to salt, thereby offering greater flexibility in bioprocessing.

Cell and Gene Therapy InsightsVol. 11(3)
c-LEcta (Germany) (DE)
Openalex Percentile: Top 63%
Viral Infectious Diseases and Gene Expression in Insects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Salt-tolerant endonucleases, the benefits for viral vector manufacturing and a comparison of two marketed enzymes — Marc Struhalla, S M Michalek · Cell and Gene Therapy Insights (2025) | TGRS Research Map | TGRS